VICTORIA, British Columbia, Dec. 15, 2017 /Weed Wire/ — Northern Vine Labs (“Company”), a subsidiary of Emerald Health Therapeutics Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) and Abattis Bioceuticals Corp. (“Abattis”) (CSE: ATT; OTC: ATTBF), today announced that Health Canada has approved an amendment to the Company’s dealer’s license.
Tag Archives: Emerald Health Therapeutics Inc.
A healthy day of trading for Canadian cannabis stocks led the North American Marijuana Index to gain several points over Monday’s 169.07 close.
VICTORIA, British Columbia, Sept. 20, 2017 /Weed Wire/ — Emerald Health Therapeutics Inc. (EHT) (TSXV:EMH) (OCTQX:EMHTF), a Canadian licensed medical producer of cannabis, is pleased to report that members of its scientific advisory team have made a novel discovery highlighting the potential of tetrahydrocannabinolic acid (THCA), a naturally occurring non-psychotropic cannabinoid, to treat Huntington’s disease and other metabolic, neurodegenerative and neuroinflammatory diseases.
VICTORIA, British Columbia, Sept. 18, 2017 /Weed Wire/ — Emerald Health Therapeutics Inc. (Therapeutics) (TSXV: EMH; OCTQX: EMHTF) has released Island Mist, its proprietary high cannabidiol (CBD) and high CBD to THC ratio dried flower product.